Atara Biotherapeutics (ATRA) Cash from Operations (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Cash from Operations came in at 3073000.0 in Q1 2026, up 89.08% YoY from 1625248.09 in Q1 2025, and up 46.06% on a QoQ basis from 5697000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Cash from Operations (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Cash from Operations data on file, last reported at 3073000.0 in Q1 2026.
- Quarterly Cash from Operations rose 89.08% year-over-year to 3073000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 25875000.0 (up 61.52% YoY) and the FY2025 annual result came in at 50940000.0, up 25.87% from the prior year.
- Cash from Operations grew to 3073000.0 in Q1 2026, from 5697000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 3073000.0 in Q1 2026 to a low of 84529000.0 in Q1 2022.
- A 5-year average of 34478647.06 and a median of 29612000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations soared 92.23% — and 2025, when it sank 145.35%.
- Tracing ATRA's Cash from Operations over 5 years: stood at 56880000.0 in 2022, then grew by 11.38% to 50406000.0 in 2023, then surged by 51.45% to 24471000.0 in 2024, then soared by 76.72% to 5697000.0 in 2025, then jumped by 46.06% to 3073000.0 in 2026.
- The last three Cash from Operations figures came in at 3073000.0 (Q1 2026), 5697000.0 (Q4 2025), and 9787000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.71 Bn | 130.86 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.60 Bn | 77.60 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.82 Bn | 59.63 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.92 Bn | 52.79 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.88 Bn | 36.78 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.46 Bn | 28.15 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 27.96 Bn | 9.57 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | -3.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.34 Mn |
| Jun 30, 2026 | -3.34 Mn |
| Mar 31, 2026 | -3.07 Mn |
| Mar 31, 2026 | -3.07 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Sep 30, 2025 | -9.79 Mn |
| Sep 30, 2025 | -9.79 Mn |
| Jun 30, 2025 | -7.32 Mn |
| Jun 30, 2025 | -7.32 Mn |
| Mar 31, 2025 | -28.14 Mn |
| Mar 31, 2025 | -28.14 Mn |
| Dec 31, 2024 | -24.47 Mn |
| Dec 31, 2024 | -24.47 Mn |
| Sep 30, 2024 | -3.99 Mn |
| Sep 30, 2024 | -3.99 Mn |
| Jun 30, 2024 | -10.65 Mn |
| Jun 30, 2024 | -10.65 Mn |
| Mar 31, 2024 | -29.61 Mn |
| Mar 31, 2024 | -29.61 Mn |